Citigroup’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-139,224
| Closed | -$32K | – | 6070 |
|
|
2024
Q4 | $32K | Buy |
139,224
+138,537
| +20,166% | +$166K | ﹤0.01% | 5194 |
|
|
2024
Q3 | $1.48K | Buy |
+687
| New | +$2.47K | ﹤0.01% | 5430 |
|
|
2024
Q2 | – | Sell |
-33,624
| Closed | -$180K | – | 5822 |
|
|
2024
Q1 | $180K | Buy |
+33,624
| New | +$233K | ﹤0.01% | 4065 |
|
|
2022
Q4 | – | Sell |
-111
| Closed | -$1K | – | 6002 |
|
|
2022
Q3 | $1K | Sell |
111
-90
| -45% | -$731 | ﹤0.01% | 5708 |
|
|
2022
Q2 | $2K | Sell |
201
-161
| -44% | -$1.51K | ﹤0.01% | 5937 |
|
|
2022
Q1 | $4K | Sell |
362
-1,291
| -78% | -$23.1K | ﹤0.01% | 5921 |
|
|
2021
Q4 | $54K | Buy |
1,653
+683
| +70% | +$27.7K | ﹤0.01% | 5026 |
|
|
2021
Q3 | $43K | Buy |
970
+321
| +49% | +$15.7K | ﹤0.01% | 4825 |
|
|
2021
Q2 | $35K | Buy |
649
+219
| +51% | +$13K | ﹤0.01% | 4994 |
|
|
2021
Q1 | $32K | Sell |
430
-12,470
| -97% | -$1.3M | ﹤0.01% | 4973 |
|
|
2020
Q4 | $1.4M | Buy |
12,900
+12,246
| +1,872% | +$1.12M | ﹤0.01% | 3213 |
|
|
2020
Q3 | $58K | Sell |
654
-6,396
| -91% | -$727K | ﹤0.01% | 5506 |
|
|
2020
Q2 | $752K | Buy |
7,050
+5,787
| +458% | +$519K | ﹤0.01% | 3852 |
|
|
2020
Q1 | $75K | Buy |
1,263
+239
| +23% | +$16.2K | ﹤0.01% | 5610 |
|
|
2019
Q4 | $71K | Buy |
1,024
+652
| +175% | +$39.5K | ﹤0.01% | 6045 |
|
|
2019
Q3 | $39K | Sell |
372
-697
| -65% | -$65.8K | ﹤0.01% | 6289 |
|
|
2019
Q2 | $99K | Buy |
1,069
+332
| +45% | +$23.1K | ﹤0.01% | 5885 |
|
|
2019
Q1 | $68K | Buy |
737
+88
| +14% | +$6.13K | ﹤0.01% | 6091 |
|
|
2018
Q4 | $36K | Sell |
649
-46
| -7% | -$3.5K | ﹤0.01% | 6500 |
|
|
2018
Q3 | $83K | Buy |
+695
| New | +$80.6K | ﹤0.01% | 6073 |
|
|
2018
Q2 | – | Sell |
-193
| Closed | -$25K | – | 7767 |
|
|
2018
Q1 | $25K | Buy |
193
+173
| +865% | +$18.9K | ﹤0.01% | 6630 |
|
|
2017
Q4 | $2K | Buy |
+20
| New | +$2.69K | ﹤0.01% | 7410 |
|
|
2017
Q3 | – | Sell |
-8
| Closed | -$1K | – | 7480 |
|
|
2017
Q2 | $1K | Sell |
8
-4
| -33% | -$628 | ﹤0.01% | 7221 |
|
|
2017
Q1 | $2K | Buy |
+12
| New | +$1.46K | ﹤0.01% | 7019 |
|
|
2016
Q4 | – | Sell |
-38
| Closed | -$5K | – | 7356 |
|
|
2016
Q3 | $5K | Buy |
+38
| New | +$4.82K | ﹤0.01% | 6787 |
|
Other funds holding SYRS
BBA
1CM
XT
Citigroup's SYRS Position: Q1 2025 in Review
Citigroup sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 139,224 shares — an estimated $32K sold.
Citigroup first reported a position in SYRS in Q3 2016 and held it in 25 quarters. The position peaked at $1.4M in Q4 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- Citigroup reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Citigroup sold 139,224 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $32K.
- Citigroup first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 25 quarters.
- Citigroup's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.4M in Q4 2020.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.